Surmodics (NASDAQ:SRDX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Surmodics (NASDAQ:SRDX – Get Rating) in a report released on Thursday morning. The firm issued a hold rating on the stock.

A number of other research firms have also issued reports on SRDX. Needham & Company LLC lowered shares of Surmodics from a buy rating to a hold rating in a report on Monday, February 13th. Barrington Research dropped their price objective on shares of Surmodics from $61.00 to $60.00 and set an outperform rating for the company in a research note on Tuesday, February 7th.

Surmodics Price Performance

Surmodics stock opened at $17.28 on Thursday. Surmodics has a 52 week low of $16.81 and a 52 week high of $45.85. The company has a current ratio of 3.73, a quick ratio of 3.00 and a debt-to-equity ratio of 0.27. The firm’s 50-day simple moving average is $26.38 and its 200 day simple moving average is $30.71.

Surmodics (NASDAQ:SRDX – Get Rating) last released its quarterly earnings data on Monday, February 6th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.13. The business had revenue of $24.93 million for the quarter, compared to analyst estimates of $24.19 million. Surmodics had a negative net margin of 31.71% and a negative return on equity of 15.61%. During the same period in the previous year, the firm earned ($0.13) EPS. On average, equities analysts predict that Surmodics will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky increased its stake in shares of Surmodics by 50.6% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 4,293 shares of the company’s stock valued at $147,000 after acquiring an additional 1,442 shares during the last quarter. Alliancebernstein L.P. increased its position in Surmodics by 2.2% during the 4th quarter. Alliancebernstein L.P. now owns 19,208 shares of the company’s stock worth $655,000 after purchasing an additional 413 shares in the last quarter. Gamco Investors INC. ET AL increased its position in Surmodics by 3.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 62,152 shares of the company’s stock worth $2,121,000 after purchasing an additional 2,352 shares in the last quarter. Soleus Capital Management L.P. increased its position in Surmodics by 0.9% during the 4th quarter. Soleus Capital Management L.P. now owns 775,311 shares of the company’s stock worth $26,454,000 after purchasing an additional 6,833 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Surmodics by 1.4% during the 4th quarter. Legal & General Group Plc now owns 35,644 shares of the company’s stock worth $1,216,000 after purchasing an additional 500 shares in the last quarter. Institutional investors and hedge funds own 96.49% of the company’s stock.

About Surmodics

(Get Rating)

Surmodics, Inc engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.